Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cytisinicline · NSC-407282

Small molecule · Agonist of nicotinic acetylcholine receptor · developed by Achieve Life Sciences

Phase 3 Most advanced trial
ACHV Developer
2 Registered trials

What is Cytisinicline?

Cytisinicline is a small-molecule nicotinic acetylcholine receptor agonist being studied for smoking and vaping cessation. It is formulated as a film-coated tablet containing 1.5 mg cytisine.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NSC-407282, cytisine
Drug type
Small molecule
Targets
nicotinic acetylcholine receptor
Mechanism
Agonist of nicotinic acetylcholine receptor
Therapy area
Psychiatry
Developer
Achieve Life Sciences (ACHV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
53S5U404NU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07392125 Phase 3 Vaping Cessation Not yet recruiting ACHV
NCT03709823 Phase 2 Smoking Cessation Completed ACHV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Vaping CessationSmoking Cessation

More from Achieve Life Sciences

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACHV page.

Follow ACHV, the company behind Cytisinicline

See ACHV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACHV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.